Diabetes Management and Dyslipidemia

Overview of Outpatient Diabetes Management

  • Outpatient diabetes management is a critical component of patient care due to its complexity.
  • Transition back to cholesterol management as it overlaps with outpatient diabetes management.

Cholesterol and Dyslipidemia Management

SAMs (Statin-Associated Muscle Symptoms)
  • Muscle symptoms related to statins (SAMs) are a common concern among patients.
  • Coenzyme Q10 (CoQ10) is often recommended by providers for muscle symptoms.
  • ACC Guidelines classify CoQ10 as having no benefit or harm (Level III).
  • If patients feel better taking CoQ10, this response is attributed to the placebo effect.
PCSK9 Inhibitors
  • Types of PCSK9 Inhibitors: Monoclonal antibodies and small interfering RNA.
    • Monoclonal Antibodies: Aliricumab (Praluent), Evolocumab (Repatha)
    • Administered via subcutaneous injections.
    • Frequency: every 2 to 4 weeks depending on indication.
    • Inclisiran: administered subcutaneously; initial dose followed by a dose every 3 months, then every 6 months.
  • Common side effect of all PCSK9 inhibitors is injection site reactions, necessitating administration in healthcare settings for monitoring.
Bempedoic Acid
  • Primary side effect to monitor is the elevation of uric acid levels, which could complicate gout management.
  • Drug interactions: simvastatin (max 20 mg) and pravastatin (max 40 mg) have dose limitations when used with bempedoic acid.

Managing High Triglycerides

Risk Assessment for Triglycerides
  • Levels less than 175: usually no significant intervention unless risk factors exist.
  • Levels between 175 and 499: assess lifestyle and medications; 10-year ASCVD risk above 7.5% warrants statin therapy.
    • Statins effectively lower triglycerides by 7-30%.
  • Levels greater than 1000: interventions to lower triglycerides are critical due to the risk of pancreatitis.
    • Intensive lifestyle modifications and specific medications (e.g., fibrates or omega-3 fatty acids) are recommended.
  • At levels between 500 and 999, consider lipid management with a focus on risk assessment.
Additional Notes on Triglyceride Management
  • Mixed EPA/DHA and EPA only are available options; only Vascepa has cardiovascular risk reduction indication.

Clinical Case Discussion

Monitoring Parameters & Risk Scoring
  • Proper lipid monitoring, assessment of family history, and lifestyle factors are essential for managing cholesterol and diabetes.
  • Use of ACC ASCVD risk estimator for risk analysis is encouraged.
  • Importance of evaluating patient management groups, such as primary vs. secondary prevention criteria.
Diabetes and Heart Risk
  • Explore diabetic management through the ABCs of diabetes care:
    • Aspirin usage (if applicable)
    • Blood pressure control
    • Cholesterol management
    • Diet management
    • Exercise promotion
    • Screening for complications
Medication Therapy & Treatment Decisions
  • Review of metformin as first-line therapy for diabetes management; its dosing and side effects must be monitored.
    • Risk of worsening renal function is critical and can lead to lactic acidosis, necessitating renal function evaluations.